Close Menu

NEW YORK – New data presented over the weekend at the American Society of Clinical Oncology's virtual annual meeting, has added to growing evidence that genomic sequencing, in particular liquid biopsy tests, can identify actionable alterations in patients with cancers of unknown primary (CUP).

Adding to this, retrospective evidence presented at the meeting showed that at least some of these tumors may respond to targeted treatments, while other studies illustrated the challenges of implementing precision medicine, including obtaining the drugs indicated by genomic profiling tests.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.